Gilead公司以7.8B美元收购Arcellx公司,以获得对Anito-cel的控制权。 Anito-cel是一种潜在的多种间皮瘤疗法,其交易在Q2 2026结束。 Gilead acquires Arcellx for $7.8B to gain control of anito-cel, a potential multiple myeloma therapy, with deal closing in Q2 2026.

Gilead Science公司同意收购生物技术公司Arcellx公司,每股现金115美元,加上每股5美元或有价值权利,价值78亿美元,预期2026年第二季度完成。 Gilead Sciences agreed to acquire biotech company Arcellx for $115 per share in cash plus a $5 contingent value right per share, valuing the deal at $7.8 billion, with completion expected in the second quarter of 2026. 该交易包括Gilead的现有股份,使Gilead完全控制Anito-cel,这是CAR T调查性细胞疗法,以治疗复发或复发性多重骨髓瘤,林业发展局正在对此进行审查,预计将在2026年12月23日前作出决定。 The transaction, which includes Gilead’s existing stake, gives Gilead full control of anito-cel, an investigational CAR T-cell therapy for relapsed or refractory multiple myeloma, which the FDA is reviewing with a decision expected by December 23, 2026. 收购的目的是加强Gilead的肿瘤管道,加速发展下一代癌症治疗。 The acquisition aims to strengthen Gilead’s oncology pipeline and accelerate development of next-generation cancer treatments.